Fresita Proteins Limited shareholders approved a special resolution authorizing borrowing powers up to ₹1,000 crore during the Annual General Meeting (AGM) held on September 30, 2026. The company, formerly known as Sarda Proteins Limited, also received unanimous consent for loans, guarantees, and investments up to the same amount under Section 186 of the Companies Act, 2013.

The meeting was conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM) in compliance with SEBI Listing Regulations. All five resolutions listed in the notice were passed with 100% votes in favour. The scrutinizer’s report confirmed that no votes were cast against any of the proposed items.

Voting Results

The voting process involved remote e-voting through NSDL and CDSL platforms, as well as e-voting during the AGM. A total of 12 members participated, casting votes for 7,243,317 shares. The turnout represented full support for the management's proposals.

Governance and Audit Updates

Shareholders ratified the appointment of M/s. A H Mandaliya & Associates, Chartered Accountants, as the Statutory Auditors of the company. Additionally, Mr. Shivam Gunvantray Zaladi (DIN: 11251860), who retired by rotation, was re-appointed as a director following his eligibility confirmation.

The AGM notice was issued on September 7, 2026, with the cut-off date for entitlement to vote set at September 23, 2026. The remote e-voting period commenced on September 26, 2026, and concluded on September 29, 2026.

What the Numbers Show

The data reveals a highly concentrated shareholder base with minimal dissent. Only 12 members voted on behalf of over 7.2 million shares, indicating that the participating equity likely represents a significant portion of the company's active voting stock or that major promoters hold a dominant stake. The unanimous passage of high-value financial authorizations, specifically the ₹1,000 crore limits for both borrowing and investments, suggests strong alignment between the board and the voting shareholders regarding the company's future capital allocation strategy.

Sarda Proteins will convene its Board of Directors on Wednesday, August 05, 2026, to deliberate on strategic capital structure adjustments. The primary agenda item involves considering proposals for raising funds through the issuance of equity shares, convertible bonds, debentures, convertible warrants, preference shares, or other equity-linked securities. This move signals the company’s intent to evaluate multiple avenues for capital infusion, potentially impacting shareholder equity and future operational capacity.

The board meeting was notified pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to the General Manager – Listing Compliance at BSE Limited, located in Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001. The company’s scrip code on the exchange is 519242.

The scope of the proposed fundraising is broad, encompassing any method permitted under applicable laws. Specifically, the company may proceed with a rights issue, private placement, preferential issue, or qualified institutions placement (QIP). These modes are governed by the Companies Act, 2013, read with the rules notified thereunder, and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Key Agenda Items

The board’s deliberations will focus on the following key areas:

Shirish Dhirajlal Savaliya, Managing Director of Sarda Proteins Limited (DIN: 08721554), signed the intimation letter on behalf of the Board of Directors. The notice also included provision for "any other items with the permission of chairperson," allowing for additional business to be transacted if deemed necessary during the session.

What This Means for Investors

The decision to explore diverse fundraising instruments indicates a proactive approach to capital management. By keeping options open for both debt (convertible bonds, debentures) and equity (shares, warrants), the company retains flexibility in choosing the most cost-effective and strategically appropriate method based on prevailing market conditions. Shareholders should monitor subsequent filings for specific details regarding the quantum of funds sought, pricing mechanisms, and the final instrument selected, which will determine the immediate impact on shareholding patterns and valuation.